Press Releases

1 min read

European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured by AGC Biologics

1 min read

AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate

1 min read

From Seattle to Chiba: Okayama University Taps AGC Biologics' Global Pathway for New Therapeutic

2 min read

AGC Biologics Expands Cell Therapy Development Operations to Asia to Serve Growing Market Need

2 min read

AGC Biologics Partners with Quell Therapeutics to Advance T-Regulatory Cell Therapies for Immune Disorders

2 min read

AGC Biologics Partners with Novelty Nobility for Cell Line Development and Phase I Preparations of Antibody Drug Candidate

2 min read

AGC Biologics Strengthens Single-Use Technology Network, Adds 5,000 L Vessels from Thermo Scientific to New Yokohama, Japan Facility

3 min read

AGC Biologics Launches New Dedicated Cell and Gene Business Division

1 min read

AGC Biologics Honored at CDMO Leadership Awards for Excellence in Quality, Biologics and Cell and Gene Therapies

2 min read

AGC Biologics’ Milan Site to Prepare Lentiviral Vector Commercial Manufacturing for Adaptimmune’s Lete-Cel Product

2 min read

Pandorum Partners with AGC Biologics to Support Clinical Manufacturing of Exosome-Based Kuragenx, a Treatment of Ulcerative Corneal Blindness

1 min read

AGC Biologics Announces Leadership Updates Amid Groundbreaking of New Yokohama Site

2 min read

New AGC Biologics CMC Jumpstart™ Program Offers CGT Developers Viral Vector Platform Assessments that Control Costs and Analyze Feasibility

2 min read

AGC Biologics to Manufacture LVV for CAR-T Therapy Approved by FDA for Autolus Therapeutics’ AUCATZYL®

2 min read

AGC Biologics Appoints Alberto Santagostino as new Chief Executive Officer

1 min read

AGC Biologics Seattle Achieves Approval for all 2024 Biologics License Applications from U.S. Food and Drug Administration, Concluding Pre-License Inspection

1 min read

AGC Biologics Begins Operations at New State-of-the-Art Manufacturing Building in Copenhagen after Successful Inspection and Licensing from Danish Medicines Agency

2 min read

CompleCure Partners with AGC Biologics’ Chiba Site to Develop Advanced Anti-Cancer Therapeutic Using Pioneering AMDC Technology

1 min read

AGC and MEDINET Strategic Partnership to Accelerate CGT CDMO Business in Japan

2 min read

AGC Biologics Strengthens Portfolio with Latest FDA Commercial Approval at Company’s Copenhagen Facility

2 min read

NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines

1 min read

AGC Biologics’ Seattle Site Achieves Successful Multi-Product Inspection by U.S. Food and Drug Administration for Biologics License Applications

2 min read

Essential Pharma and AGC Biologics Partner on late-phase clinical manufacturing of immunotherapy candidate for the treatment of high-risk neuroblastoma

1 min read

AGC Biologics Appointments Ben Clauberg as Vice President, Business Development of European Market

1 min read

AGC Biologics & CEO Patricio Massera Announce Plans for Him to Step Down

2 min read

AGC Biologics Completes Copenhagen Campus Expansion, Doubling Single-use Mammalian Bioreactor Capacity at Site

2 min read

AGC Biologics and BioConnection Partner to Offer New End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering

1 min read

AGC Biologics selects Cytiva to provide FlexFactory platforms in new biomanufacturing facility in Japan

1 min read

AGC Biologics Announces Successful Completion of Production of Cancer-Specific Therapeutic Antibody Fragments with Var2 Pharmaceuticals

2 min read

AGC Biologics Strengthens Executive Leadership with Appointment of Dr. Christoph Winterhalter as Chief Business Officer

2 min read

AGC Biologics to Manufacture First-ever FDA Approved Gene Therapy for Early-onset MLD, Orchard Therapeutics’ Lenmeldy™

1 min read

AGC Biologics announces plans for New Manufacturing Site in Yokohama Japan

2 min read

Research: Protein A Capture Technology Offers 10X Productivity Over Standard Resin Columns for Antibody Purification

1 min read

AGC Biologics to Prepare Late-Phase and Commercial Runs for Immunocore

1 min read

AGC Biologics Milan Honored for Leadership and Innovation

1 min read

AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product

1 min read

AGC Biologics Completes pDNA and mRNA Expansion at Heidelberg location

1 min read

AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months

2 min read

AGC Biologics Expands Cell Suites at Longmont ATMP Campus

1 min read

AGC Biologics Partners with Asahi Kasei Pharma Corporation on Clinical Antibody Project

1 min read

AGC Biologics Completes Expansion at Milan Cell and Gene Therapy Development and Manufacturing Site

1 min read

AGC Biologics Introduces AGCellerate™, Offering Fast Timelines, Fixed Pricing and Guaranteed Product Quantity

2 min read

AGC Biologics Launches BravoAAV™ and ProntoLVV™ Platforms

1 min read

AGC Biologics Receives Bioprocessing Excellence Award in Japan for Work at Chiba Site

1 min read

AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic pulmonary fibrosis (IPF) Project

1 min read

AGC Biologics Copenhagen named Børsen Gazelle company for 2022

1 min read

Genenta and AGC Biologics Expand Development & Manufacturing Agreement

2 min read

AGC Biologics Commercially Manufacture Provention Bio Diabetes Therapy

2 min read

AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies

1 min read

AGC Biologics Receives Excellence in Innovation and Leadership by Le Fonti Business News in Italy

1 min read

AGC Biologics Honored for Innovations in Cell Line Development

2 min read

AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate

2 min read

RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies

1 min read

AGC Biologics Supports Altheia Science’s Gene Therapy Programs

1 min read

AGC Biologics Named Manufacturing Company of the Year by American Business Awards

2 min read

AGC Biologics Honored as a Top 10 Company for Pharma Quality Assurance

1 min read

Tony Fraij Joins Colorado BioScience Association Board of Directors

2 min read

AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus

1 min read

AGC Biologics Provides Aid to Ukraine

1 min read

Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate

1 min read

AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate with pDNA Starting Material

1 min read

AGC Biologics Names Regina Choi-Rivera General Manager of Boulder Site

1 min read

AGC Biologics Appoints Whitney Sandberg as the new Vice President of Quality for its Colorado Facilities

1 min read

I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project

2 min read

AGC Biologics Receives Transatlantic Award for Investments in Milan Biopharmaceutical Industry

2 min read

4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab

1 min read

AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer

2 min read

AGC Biologics Expands pDNA and mRNA Manufacturing Capacity

2 min read

AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site

1 min read

AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site

1 min read

AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings

1 min read

AGC Biologics Appoints Kevin Ingham as the new General Manager/Site Head of their Seattle, Washington Site

2 min read

AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings

4 min read

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

1 min read

AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine

2 min read

AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics

2 min read

Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

1 min read

Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase injection) at AGC’s Copenhagen Facility

1 min read

AGC Biologics Expands Partnership with Rocket Pharmaceuticals

1 min read

AGC Biologics Appoints Jun Takami to General Manager/Site Head of Their Chiba, Japan Site

2 min read

AGC Biologics to Present Their End-to-End Cell and Gene Therapy Offering at ARM’s Meeting on the Mediterranean Conference

1 min read

AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy

1 min read

AGC Biologics Appoints David Stewart as the New General Manager/Site Head of the Boulder, Colorado Site

3 min read

AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics’ Newly Approved Libmeldy™

2 min read

Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004

1 min read

AGC Biologics to Expand Biopharmaceutical CDMO Capacity

2 min read

AGC Biologics and Horizon Therapeutics plc Expand Partnership

1 min read

MolMed S.p.A Becomes AGC Biologics S.p.A Following the July Acquisition

2 min read

AGC Biologics Shifts Leadership Structure at United States and Copenhagen Sites to Support the Continued Development and Growth of the Regions

2 min read

AGC Biologics Appoints Luca Alberici as the New General Manager/Site Head of the Milan, Italy Site

2 min read

AGC Biologics Completes PPQ Manufacturing with Provention Bio for Type 1 Diabetes Product Candidate, Teplizumab

1 min read

AGC Biologics Enters into Partnership as a CDMO with Ono Pharmaceuticals to Manufacture Biopharmaceuticals at Clinical Development Stage

2 min read

AGC Biologics Expands Partnership with Novavax

1 min read

AGC to Complete the Acquisition of MolMed on July 31, 2020

2 min read

AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin® Program

1 min read

AGC Biologics Expands Development Capacities for pDNA Services at Heidelberg Site

2 min read

Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing

2 min read

Saiba AG Selects AGC Biologics to Develop and Produce COVID-19 Vaccine

2 min read

Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine

1 min read

AGC Biologics Acquires Commercial Facility, Expanding Global Service Offerings

2 min read

Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)

2 min read

AGC Biologics to Participate in First-Ever BIO Digital Conference

2 min read

AGC Biologics Partners with Faron Pharmaceuticals to Manufacture Cancer Treatment

AGC Biologics Manufactures Key Ingredient in Potential COVID-19 Treatment Drug, Leronlimab

2 min read

AdaptVac Partners with AGC Biologics to Develop & Produce COVID-19 Vaccine

AGC Biologics in the news for our work toward COVID-19 treatment

2 min read

AGC Inc. Decides to Launch Voluntary Tender Offer for Shares of Molmed

AGC Biologics Plasmid Production

2 min read

Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseases

2 min read

AGC Biologics Expands Plasmid DNA Offering

1 min read

AGC Biologics’ $18m Investment in Seattle and Denmark Facilities Strengthens Global Footprint

1 min read

AGC Biologics Appoints New Site Head/General Manager  of Copenhagen, Denmark Operations

2 min read

AGC Biologics Appoints New Chief Technical Officer

1 min read

AGC Biologics Appoints New Site Head/General Manager of Bothell, WA Operations

1 min read

U.S. Congresswoman, Suzan DelBene, Visits AGC Biologics Corporate Headquarters

1 min read

Washington State Governor Jay Inslee Visits AGC Biologics Corporate Headquarters

2 min read

AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002